Afatinib is an irreversible second generation pan-ErbB inhibitor developed as a first-line treatment of patients with metastatic NSCLC whose tumors harbor EGFR mutations or deletions as well as in patients with metastatic disease that progressed after platinum-based chemotherapy [34]. The gene discussed is EGFR; the disease is metastatic neoplasm.